Please use this identifier to cite or link to this item: https://doi.org/10.3389/fimmu.2021.734293
Title: Epstein–Barr Virus Epithelial Cancers—A Comprehensive Understanding to Drive Novel Therapies
Authors: Han, Shuting
Tay, Joshua K. 
Loh, Celestine Jia Ling
Chu, Axel Jun Ming
Yeong, Joe Poh Sheng
Lim, Chwee Ming
Toh, Han Chong 
Keywords: Epstein–Barr virus
gastric cancer
lymphoepithelioma-like carcinoma
nasopharyngeal cancer
tumour microenvironment
Issue Date: 10-Dec-2021
Publisher: Frontiers Media S.A.
Citation: Han, Shuting, Tay, Joshua K., Loh, Celestine Jia Ling, Chu, Axel Jun Ming, Yeong, Joe Poh Sheng, Lim, Chwee Ming, Toh, Han Chong (2021-12-10). Epstein–Barr Virus Epithelial Cancers—A Comprehensive Understanding to Drive Novel Therapies. Frontiers in Immunology 12 : 734293. ScholarBank@NUS Repository. https://doi.org/10.3389/fimmu.2021.734293
Rights: Attribution 4.0 International
Abstract: Epstein–Barr virus (EBV) is a ubiquitous oncovirus associated with specific epithelial and lymphoid cancers. Among the epithelial cancers, nasopharyngeal carcinoma (NPC), lymphoepithelioma-like carcinoma (LELC), and EBV-associated gastric cancers (EBVaGC) are the most common. The role of EBV in the pathogenesis of NPC and in the modulation of its tumour immune microenvironment (TIME) has been increasingly well described. Much less is known about the pathogenesis and tumour–microenvironment interactions in other EBV-associated epithelial cancers. Despite the expression of EBV-related viral oncoproteins and a generally immune-inflamed cancer subtype, EBV-associated epithelial cancers have limited systemic therapeutic options beyond conventional chemotherapy. Immune checkpoint inhibitors are effective only in a minority of these patients and even less efficacious with molecular targeting drugs. Here, we examine the key similarities and differences of NPC, LELC, and EBVaGC and comprehensively describe the clinical, pathological, and molecular characteristics of these cancers. A deeper comparative understanding of these EBV-driven cancers can potentially uncover targets in the tumour, TIME, and stroma, which may guide future drug development and cast light on resistance to immunotherapy. Copyright © 2021 Han, Tay, Loh, Chu, Yeong, Lim and Toh.
Source Title: Frontiers in Immunology
URI: https://scholarbank.nus.edu.sg/handle/10635/233513
ISSN: 1664-3224
DOI: 10.3389/fimmu.2021.734293
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3389_fimmu_2021_734293.pdf4.18 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

3
checked on Dec 2, 2022

Page view(s)

18
checked on Dec 1, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons